Exerkines: The Signals Exercising Muscle Sends Around the Body


When a muscle works, it does not only burn fuel. It also releases chemical messages into the blood, and other organs — fat, liver, bone and brain — respond to them. Scientists call these messages exerkines (exercise signals), and the ones that come from muscle itself myokines. The idea explains part of why exercise seems to help so many organs at once, and it has produced some famous molecules: interleukin-6, irisin, beta-aminoisobutyric acid, lactate, fibroblast growth factor 21, apelin, meteorin-like and osteocalcin. This page goes through each one and separates what was measured in people from what was found in mice or in cells, because the two often tell different stories. It also covers whether any of these signals can be taken as a pill, and what is still not known.

For the broad evidence on exercise itself — how much, and what it does for the heart, metabolism, mood and ageing — see the main Exercise page. One of the signals below has its own full page: BAIBA (beta-aminoisobutyric acid).


Table of Contents

  1. Exerkines Are Messages Released by Exercise
  2. Interleukin-6 Was the First Signal Traced to Working Human Muscle
  3. Irisin Became Famous Before It Could Be Measured
  4. Beta-Aminoisobutyric Acid Rises a Little in People and Acts Strongly in Mice
  5. Lactate Is a Fuel and a Signal, Not Just Waste
  6. Fibroblast Growth Factor 21 Comes From the Liver
  7. Apelin, Meteorin-Like and Osteocalcin Are Newer Candidates
  8. What the Records Report for Blood Sugar, Fat, Bone and Brain
  9. Most Findings Come From Mice, and Human Data Often Differ
  10. Exerkines as Pills: What Trials Have Tested
  11. What Is Not Known
  12. Key Research Papers
  13. Connections
  14. Featured Videos

Exerkines Are Messages Released by Exercise

A 2022 review by a large group of exercise scientists defines exerkines as signalling molecules released in response to a single bout of exercise, to regular training, or to both. They act on distant organs (like a hormone), on nearby cells, or on the same cell that made them. The same review notes that many tissues release them, and gives each group a name:

The review dates the field to the discovery in 2000 that contracting muscle releases interleukin-6, and says that since then the number of known exercise-linked signalling molecules has multiplied. It describes their possible roles in heart, metabolic, immune and brain health, and their potential for treating cardiovascular disease, type 2 diabetes and obesity. In the same breath it states that the molecular mechanisms behind the benefits of exercise “remain poorly understood”.

Two points help when reading claims about any single exerkine:

Back to Table of Contents

Interleukin-6 Was the First Signal Traced to Working Human Muscle

Interleukin-6 (IL-6) is described in the research as a key regulator of immune function. Its role in exercise is a different one, and it is the best-documented exerkine in people.

In people — muscle releases it. In a 2000 study, six healthy men straightened one knee over and over against a light load for five hours (25 watts, 40% of their peak power) while researchers sampled blood going into and coming out of both legs. Interleukin-6 in arterial blood rose 19-fold compared with rest. The working leg released interleukin-6 into the blood; the resting leg did not release a significant amount. The amount released by the muscle over the last two hours was 17-fold higher than the rise seen in the blood, which the authors read as a very fast turnover. They suggested that interleukin-6 from contracting muscle helps keep blood sugar steady during long exercise.

In people — it moves fat. In a 2003 study, 18 healthy men received a three-hour infusion of either salt water or one of two doses of lab-made human interleukin-6. Both doses raised fatty acids in the blood, and these levels reached about 50% above the salt-water group by the end of the infusion and stayed raised for at least three hours afterwards. Whole-body fat burning rose after the second hour. At the low dose the change happened without any change in adrenaline, insulin or glucagon, and the authors observed no adverse side effects.

In people — blocking it changed the result of exercise. This is the strongest human test of any exerkine. In a 2019 randomized, placebo-controlled trial, adults with abdominal obesity were given either tocilizumab (a drug that blocks the interleukin-6 receptor) or a placebo during a 12-week program of either bicycle exercise or no exercise. Exercise reduced visceral fat (the fat around the organs), but this effect was abolished when interleukin-6 was blocked. Lean body mass did not differ between groups. The trial also found that blocking interleukin-6 raised cholesterol levels, and exercise did not reverse that. The authors conclude that interleukin-6 is required for exercise to reduce visceral fat in this setting. More about the drug itself is on the tocilizumab page.

The same molecule rising during exercise and during infection can be confusing. The records above describe short, sharp pulses from working muscle; they do not address long-term raised interleukin-6 in chronic disease, which is a separate topic covered on the inflammatory markers page.

Back to Table of Contents

Irisin Became Famous Before It Could Be Measured

Irisin is the exerkine most often named in popular articles, and its story is a useful warning about how fast a mouse finding can outrun the human evidence.

2012 — the discovery (mice). A study in Nature reported that a muscle protein called fibronectin type III domain-containing protein 5 is cut and released into the blood as a new hormone, which the authors named irisin. In mice, irisin acted on white fat cells, in dishes and in living animals, to switch on a brown-fat-like (heat-producing) program. Mildly raising irisin in the blood increased energy use in mice without changes in movement or food intake, and improved obesity and blood sugar control. The paper also stated that irisin is induced with exercise in mice and in humans.

2013 — a genetic doubt (human genes and cells). A team analysing the gene found that in rodents and most primates it starts with the usual “start” signal, but in humans that signal carries a mutation (ATG changed to ATA). Human cells given the human version of the gene made only 1% of the full-length protein made from the usual start signal. In muscle samples from two human exercise studies, the gene's activity was not changed by endurance or strength training, and human fat-precursor cells did not turn “brite” (brown-like) when given irisin. The authors judged it “rather unlikely” that the effects seen in mice would carry over to humans.

2014–2015 — a measurement problem. A 2014 review noted that different studies using different commercial antibody test kits reported human irisin levels over a wide range, and that human cell models showed no browning of the main white fat stores. In 2015, a group tested the antibodies inside four commercial kits and found that they reacted strongly with other, unrelated proteins in human and animal blood. They concluded that their results “call into question all previous data obtained with commercial ELISA kits for irisin” and titled the paper “Irisin — a myth rather than an exercise-inducible myokine.”

2015 — mass spectrometry (people). The original discovery group then measured irisin with mass spectrometry, a method that identifies molecules by their exact weight, using heavy-isotope reference peptides as internal standards. They reported that human irisin is made mainly from the unusual ATA start signal and circulates at about 3.6 nanograms per millilitre in sedentary people and about 4.3 nanograms per millilitre in people doing aerobic interval training. Their conclusion: human irisin exists, circulates and is regulated by exercise.

Since then — mixed human results. In a 2023 study that measured 16 exerkines in young sedentary adults before and after exercise, irisin was among the molecules that were “not modified or not detectable”.

Where that leaves irisin: by mass spectrometry it is real and present in human blood at low levels, and the difference measured between sedentary and training people was small (about 3.6 versus 4.3 nanograms per millilitre). Many older human studies that used antibody kits are hard to interpret. The brown fat animation on this site shows the heat-making process irisin was proposed to drive.

Back to Table of Contents

Beta-Aminoisobutyric Acid Rises a Little in People and Acts Strongly in Mice

Beta-aminoisobutyric acid (BAIBA) is a small amino-acid-like molecule, not a protein, which is why later papers call it an exerkine or “metabokine” rather than a myokine. Its full story — the two mirror-image forms, the gene that sets each person's level, and the supplement trials — is on the BAIBA page. In brief:

The only outcome trial of beta-aminoisobutyric acid as a supplement in people found no effect on body composition or metabolism (see the section on pills below).

Back to Table of Contents

Lactate Is a Fuel and a Signal, Not Just Waste

Lactate (often called lactic acid) was long thought of as a waste product of exercise without enough oxygen. A 2018 review of “lactate shuttle” research states that lactate is formed continuously even when oxygen is plentiful, and that moving between the cells that make it and the cells that use it, it serves at least three purposes: a major energy source, the main raw material the body uses to make new glucose, and a signalling molecule. The review adds that some clinicians now see raised blood lactate as a sign of “strain” rather than “stress”, and that clinical studies are using lactate to treat inflammatory conditions and to fuel working muscles in sports medicine. The lactate and Cori cycle animation shows how lactate moves between muscle and liver, and the lactate lab test page covers what blood levels mean in hospital medicine.

Back to Table of Contents

Fibroblast Growth Factor 21 Comes From the Liver

Fibroblast growth factor 21 (FGF21) is a hormone that rises in the blood after exercise, and studies of exerkines include it in their lists. A 2016 human study points to the liver as its source during exercise, which makes it a hepatokine.

Fibroblast growth factor 21 is also the exerkine that has gone furthest as a medicine, in the form of an engineered long-acting version of the protein (see the section on pills). Other pages on this site discuss it in the context of methionine restriction.

Back to Table of Contents

Apelin, Meteorin-Like and Osteocalcin Are Newer Candidates

Apelin

A 2018 study reported that apelin, a small peptide, is produced in response to muscle contraction, and that its production falls with age in both humans and rodents.

The authors proposed apelin as a possible early marker of age-related muscle loss (sarcopenia) and a target for future drugs. No human treatment trial appears in the record. Muscle loss with age is covered on the creatine and sarcopenia page.

Meteorin-Like

Meteorin-like was identified in 2014 as a circulating factor made in muscle after exercise and in fat after cold exposure.

Osteocalcin

Osteocalcin is a protein made by bone-building cells. One form of it, called undercarboxylated osteocalcin, acts as a hormone. Its activation depends on vitamin K, which is why it appears on the vitamin K and insulin sensitivity page.

Back to Table of Contents

What the Records Report for Blood Sugar, Fat, Bone and Brain

Blood sugar

In people, interleukin-6 from working muscle was proposed to help hold blood sugar steady during long exercise, and the hormones that control blood sugar (glucagon and insulin) drive the exercise rise in fibroblast growth factor 21. In mice, beta-aminoisobutyric acid, irisin, meteorin-like and osteocalcin each improved blood sugar control or glucose use. In people, the human links for beta-aminoisobutyric acid and meteorin-like are associations, and for meteorin-like the association runs the opposite way. See the insulin resistance section for approaches tested in people.

Fat tissue and “browning”

Turning white fat into heat-burning beige fat was the headline claim for irisin, beta-aminoisobutyric acid and meteorin-like — all shown in mice or in cells. Human fat-precursor cells did not brown when given irisin in the 2013 study. The clearest human result about fat is a different one: blocking interleukin-6 cancelled the loss of visceral fat that exercise produced over 12 weeks. Cold exposure is the other common trigger studied for brown fat.

Bone and muscle

Bone talks back to muscle through osteocalcin (mostly mouse evidence, with a human rise after interval cycling). Apelin's role in ageing muscle comes from mice, with human associations. The bone-cell findings for beta-aminoisobutyric acid, also mostly in mice, are on the BAIBA page.

Brain

All the direct brain evidence is from animals:

In people, the 2023 study of 16 exerkines found brain-derived neurotrophic factor in the blood rose three minutes after a maximal walking test. That is a blood measurement, not a brain one. The brain aging page covers what has been tested on memory and thinking in people.

Back to Table of Contents

Most Findings Come From Mice, and Human Data Often Differ

Nearly every exerkine on this page was discovered and given its job description in mice. The human records repeatedly show a weaker or different picture, for several reasons that appear in the studies themselves:

The human evidence that stands out is short-term and specific: muscle does release interleukin-6 while working; interleukin-6 does mobilise fat when infused; and blocking interleukin-6 did remove one effect of 12 weeks of exercise on visceral fat. For most other exerkines, the human record is measurements in the blood and associations.

Back to Table of Contents

Exerkines as Pills: What Trials Have Tested

If exercise works partly through these signals, an obvious question is whether they can be taken directly. The human trial record is small.

None of the records read for this page shows a pill or injection reproducing the overall effects of exercise in people. The phrase “exercise pill” appears in a mouse study of lactate, not in a human trial. For the questions supplement labels raise, see BAIBA, which sets out the full human record of a product sold on exerkine claims.

Back to Table of Contents

What Is Not Known

Exercise itself has a much larger body of human evidence than any single exerkine; that evidence is summarised on the Exercise page.

Back to Table of Contents

Key Research Papers

  1. Chow LS, Gerszten RE, Taylor JM, et al. Exerkines in health, resilience and disease. Nat Rev Endocrinol. 2022;18(5):273-289. PubMed PMID: 35304603
  2. Steensberg A, van Hall G, Osada T, et al. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol. 2000;529 Pt 1(Pt 1):237-42. PubMed PMID: 11080265
  3. van Hall G, Steensberg A, Sacchetti M, et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab. 2003;88(7):3005-10. PubMed PMID: 12843134
  4. Wedell-Neergaard AS, Lang Lehrskov L, Christensen RH, et al. Exercise-Induced Changes in Visceral Adipose Tissue Mass Are Regulated by IL-6 Signaling: A Randomized Controlled Trial. Cell Metab. 2019;29(4):844-855.e3. PubMed PMID: 30595477
  5. Boström P, Wu J, Jedrychowski MP, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463-8. PubMed PMID: 22237023
  6. Raschke S, Elsen M, Gassenhuber H, et al. Evidence against a beneficial effect of irisin in humans. PLoS One. 2013;8(9):e73680. PubMed PMID: 24040023
  7. Elsen M, Raschke S, Eckel J. Browning of white fat: does irisin play a role in humans? J Endocrinol. 2014;222(1):R25-38. PubMed PMID: 24781257
  8. Albrecht E, Norheim F, Thiede B, et al. Irisin - a myth rather than an exercise-inducible myokine. Sci Rep. 2015;5:8889. PubMed PMID: 25749243
  9. Jedrychowski MP, Wrann CD, Paulo JA, et al. Detection and Quantitation of Circulating Human Irisin by Tandem Mass Spectrometry. Cell Metab. 2015;22(4):734-740. PubMed PMID: 26278051
  10. Mendez-Gutierrez A, Aguilera CM, Osuna-Prieto FJ, et al. Exercise-induced changes on exerkines that might influence brown adipose tissue metabolism in young sedentary adults. Eur J Sport Sci. 2023;23(4):625-636. PubMed PMID: 35152857
  11. Roberts LD, Boström P, O'Sullivan JF, et al. β-Aminoisobutyric acid induces browning of white fat and hepatic β-oxidation and is inversely correlated with cardiometabolic risk factors. Cell Metab. 2014;19(1):96-108. PubMed PMID: 24411942
  12. Stautemas J, Van Kuilenburg ABP, Stroomer L, et al. Acute Aerobic Exercise Leads to Increased Plasma Levels of R- and S-β-Aminoisobutyric Acid in Humans. Front Physiol. 2019;10:1240. PubMed PMID: 31611815
  13. Daou HN, Watt NT, Gad SA, et al. The metabokine β-aminoisobutyric acid mediates exercise performance and skeletal muscle adaptation through a PGC1α-BAIBA-PPARδ axis. Nat Commun. 2026;17(1):8090. PubMed PMID: 42613329
  14. Allen LE, Sutton PJ, Schrautemeier A, et al. Effects of L-BAIBA supplementation with and without grains of paradise on changes in resting metabolic rate, body composition, and cardiometabolic risk factors. Nutr J. 2026;25(1):92. PubMed PMID: 42271377
  15. Brooks GA. The Science and Translation of Lactate Shuttle Theory. Cell Metab. 2018;27(4):757-785. PubMed PMID: 29617642
  16. El Hayek L, Khalifeh M, Zibara V, et al. Lactate Mediates the Effects of Exercise on Learning and Memory through SIRT1-Dependent Activation of Hippocampal Brain-Derived Neurotrophic Factor (BDNF). J Neurosci. 2019;39(13):2369-2382. PubMed PMID: 30692222
  17. Hansen JS, Pedersen BK, Xu G, et al. Exercise-Induced Secretion of FGF21 and Follistatin Are Blocked by Pancreatic Clamp and Impaired in Type 2 Diabetes. J Clin Endocrinol Metab. 2016;101(7):2816-25. PubMed PMID: 27163358
  18. Harrison SA, Frias JP, Lucas KJ, et al. Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study. Clin Gastroenterol Hepatol. 2025;23(1):103-113. PubMed PMID: 38447814
  19. Vinel C, Lukjanenko L, Batut A, et al. The exerkine apelin reverses age-associated sarcopenia. Nat Med. 2018;24(9):1360-1371. PubMed PMID: 30061698
  20. Rao RR, Long JZ, White JP, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell. 2014;157(6):1279-1291. PubMed PMID: 24906147
  21. Alizadeh A, Alizadeh H. Downhill running exercise increases circulating level of myokine meteorin-like hormone in humans. J Sports Med Phys Fitness. 2022;62(5):700-704. PubMed PMID: 34313414
  22. Chung HS, Hwang SY, Choi JH, et al. Implications of circulating Meteorin-like (Metrnl) level in human subjects with type 2 diabetes. Diabetes Res Clin Pract. 2018;136:100-107. PubMed PMID: 29199003
  23. Mera P, Laue K, Ferron M, et al. Osteocalcin Signaling in Myofibers Is Necessary and Sufficient for Optimum Adaptation to Exercise. Cell Metab. 2016;23(6):1078-1092. PubMed PMID: 27304508
  24. Levinger I, Yan X, Bishop D, et al. The influence of α-actinin-3 deficiency on bone remodelling markers in young men. Bone. 2017;98:26-30. PubMed PMID: 28254467
  25. Wrann CD, White JP, Salogiannnis J, et al. Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. Cell Metab. 2013;18(5):649-59. PubMed PMID: 24120943
  26. Lourenco MV, Frozza RL, de Freitas GB, et al. Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer's models. Nat Med. 2019;25(1):165-175. PubMed PMID: 30617325

PubMed Topic Searches

  1. PubMed: exerkines
  2. PubMed: muscle interleukin-6 during exercise in humans
  3. PubMed: irisin measured by mass spectrometry
  4. PubMed: fibroblast growth factor 21 and exercise in humans
  5. PubMed: meteorin-like and exercise

Back to Table of Contents

Connections

Back to Table of Contents